Glucocorticoid therapy in respiratory illness: bench to bedside. J Investig Med 2022 Dec;70(8):1662-1680
Date
06/29/2022Pubmed ID
35764344Pubmed Central ID
PMC9726965DOI
10.1136/jim-2021-002161Scopus ID
2-s2.0-85134601973 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Each year, hundreds of millions of individuals are affected by respiratory disease leading to approximately 4 million deaths. Most respiratory pathologies involve substantially dysregulated immune processes that either fail to resolve the underlying process or actively exacerbate the disease. Therefore, clinicians have long considered immune-modulating corticosteroids (CSs), particularly glucocorticoids (GCs), as a critical tool for management of a wide spectrum of respiratory conditions. However, the complex interplay between effectiveness, risks and side effects can lead to different results, depending on the disease in consideration. In this comprehensive review, we present a summary of the bench and the bedside evidence regarding GC treatment in a spectrum of respiratory illnesses. We first describe here the experimental evidence of GC effects in the distal airways and/or parenchyma, both in vitro and in disease-specific animal studies, then we evaluate the recent clinical evidence regarding GC treatment in over 20 respiratory pathologies. Overall, CS remain a critical tool in the management of respiratory illness, but their benefits are dependent on the underlying pathology and should be weighed against patient-specific risks.
Author List
Amratia DA, Viola H, Ioachimescu OCAuthor
Octavian C. Ioachimescu MD, PhD Vice Chair, Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsGlucocorticoids
